Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Cigna's first-quarter financial results got ... which allows clients to lock in savings guarantees or to cap GLP-1 spending when covering the medications for weight loss. It also provides clinical ...

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk (NVO) and Eli Lilly (NYSE ...

Cigna is doubling ... also link patients to copay assistance programs for which they may be eligible. Evanko noted that one in ten Americans is set to be on a GLP-1 drug, but significant barriers ...

The GLP-1 drugs are currently only covered by half of The Cigna Group (NYSE:CI)’s clients. Customers who now provide coverage could save as much as 20%. The agreement comes after Lilly’s ...

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced ...

Cigna’s (NYSE:CI) health services arm ... Zepbound. The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200 under the new offering. Patients can save as much ...